Overview

Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Studying samples of blood and tissue from patients with basal cell nevus syndrome and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to basal cell nevus syndrome. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sirolimus may keep basal cell skin cancer from forming in patients with basal cell nevus syndrome. PURPOSE: This phase I trial is studying topical sirolimus in patients with basal cell nevus syndrome and in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Everolimus
Sirolimus